COMBINATION THERAPY INCLUDING BETA-SITOSTEROL IN COMBINATION WITH AT LEAST ONE OF A BRAF INHIBITOR, A MEK INHIBITOR AND AN ERK INHIBITOR AND METHODS AND USE THEREOF

摘要

The present invention relates in a first aspect to a pharmaceutical composition comprising beta-sitosterol or a homolog thereof in combination with a BRAF inhibitor and/or a MEK inhibitor and/or an ERK inhibitor. In particular, the present invention relates to a combination of the beta-sitosterol in combination with a BRAF inhibitor like vemurafenib, PLX4720 or dabrafenib or the MEK inhibitor trametinib. The composition is particularly useful in the treatment of cancer including metastatic cancer for example by oral or intravenous administration of both. The beta-sitosterol and the at least one of the BRAF inhibitor and/or MEK inhibitor and/or an ERK inhibitor being administered simultaneously, separately or sequentially. In a further aspect, a method of treating individuals suffering from cancer using the pharmaceutical composition according to the present invention is disclosed.